Abivax SA

Abivax Sa. ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
  • TickerABVX
  • ISINFR0012333284
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Eric Le Berrigaud

ABIVAX Initiation of coverage | Corporate, FV EUR37.5 | Will ABX464 be partnered or Abivax acquired?

ABIVAX Initiation of coverage | Corporate, FV EUR37.5 | Will ABX464 be partnered or Abivax acquired? We expect Abivax to be one of the hottest topics in the biotech space in 2020.

Abivax: 1 director bought

A director at Abivax bought 13,800 shares at 10.765EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board membe...

Eric Le Berrigaud

ABIVAX Initiation of coverage | Corporate, FV EUR37.5 | Will ABX464 be partnered or Abivax acquired?

ABIVAX Initiation of coverage | Corporate, FV EUR37.5 | Will ABX464 be partnered or Abivax acquired? We expect Abivax to be one of the hottest topics in the biotech space in 2020.

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Christophe DOMBU

Deuxième étude de phase 2a avec ABX464 dans le VIH

Abivax vient de recevoir l’aval des autorités réglementaires pour mener une étude de phase 2a en Europe, avec son produit ABX464 indiqué pour le traitement des infections au VIH. Cette étude intervient après la publication de résultats positifs d’une première étude de phase 2a établissant la première preuve d’efficacité de ce médicament first-in-class chez l’homme. La soci